313 related articles for article (PubMed ID: 22103487)
21. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
22. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.
Griffioen AW; Molema G
Pharmacol Rev; 2000 Jun; 52(2):237-68. PubMed ID: 10835101
[TBL] [Abstract][Full Text] [Related]
23. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
Hess C; Vuong V; Hegyi I; Riesterer O; Wood J; Fabbro D; Glanzmann C; Bodis S; Pruschy M
Br J Cancer; 2001 Dec; 85(12):2010-6. PubMed ID: 11747347
[TBL] [Abstract][Full Text] [Related]
24. Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand".
Rak J; Yu JL
Semin Cancer Biol; 2004 Apr; 14(2):93-104. PubMed ID: 15018893
[TBL] [Abstract][Full Text] [Related]
25. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-6: an angiogenic target in solid tumours.
Middleton K; Jones J; Lwin Z; Coward JI
Crit Rev Oncol Hematol; 2014 Jan; 89(1):129-39. PubMed ID: 24029605
[TBL] [Abstract][Full Text] [Related]
27. [VEGF, anti-vEGF and diseases].
Corvol P
Bull Acad Natl Med; 2008 Feb; 192(2):289-300; discussion 300-2. PubMed ID: 18819684
[TBL] [Abstract][Full Text] [Related]
28. Mitochondria as targets in angiogenesis inhibition.
Park D; Dilda PJ
Mol Aspects Med; 2010 Feb; 31(1):113-31. PubMed ID: 19995570
[TBL] [Abstract][Full Text] [Related]
29. Tumour vasculature as a target for anticancer therapy.
Eatock MM; Schätzlein A; Kaye SB
Cancer Treat Rev; 2000 Jun; 26(3):191-204. PubMed ID: 10814561
[TBL] [Abstract][Full Text] [Related]
30. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.
Glade Bender J; Cooney EM; Kandel JJ; Yamashiro DJ
Drug Resist Updat; 2004; 7(4-5):289-300. PubMed ID: 15533766
[TBL] [Abstract][Full Text] [Related]
31. [Role of angiogenesis in the growth and progression of tumors. Treatment with angiogenesis inhibitors: from promising results in experimental animal models to the reality of clinical use].
Plavetić ND; Letilović T; Vrbanec D
Lijec Vjesn; 2003; 125(9-10):260-5. PubMed ID: 15038217
[TBL] [Abstract][Full Text] [Related]
32. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.
De Bock K; Cauwenberghs S; Carmeliet P
Curr Opin Genet Dev; 2011 Feb; 21(1):73-9. PubMed ID: 21106363
[TBL] [Abstract][Full Text] [Related]
33. Tumor vasculature: the Achilles' heel of cancer?
Johannessen TC; Wagner M; Straume O; Bjerkvig R; Eikesdal HP
Expert Opin Ther Targets; 2013 Jan; 17(1):7-20. PubMed ID: 23121690
[TBL] [Abstract][Full Text] [Related]
34. Response to anti-angiogenesis: an ever changing feature.
Bertolini F
Breast; 2011 Oct; 20 Suppl 3():S61-2. PubMed ID: 22015295
[TBL] [Abstract][Full Text] [Related]
35. Synopsis of angiogenesis inhibitors in oncology.
Ellis LM; Liu W; Fan F; Jung YD; Reinmuth N; Stoeltzing O; Takeda A; Akagi M; Parikh AA; Ahmad S
Oncology (Williston Park); 2002 May; 16(5 Suppl 4):14-22. PubMed ID: 12102576
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of histone demethylase JMJD1A improves anti-angiogenic therapy and reduces tumor-associated macrophages.
Osawa T; Tsuchida R; Muramatsu M; Shimamura T; Wang F; Suehiro J; Kanki Y; Wada Y; Yuasa Y; Aburatani H; Miyano S; Minami T; Kodama T; Shibuya M
Cancer Res; 2013 May; 73(10):3019-28. PubMed ID: 23492365
[TBL] [Abstract][Full Text] [Related]
37. Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours.
Zaffryar-Eilot S; Marshall D; Voloshin T; Bar-Zion A; Spangler R; Kessler O; Ghermazien H; Brekhman V; Suss-Toby E; Adam D; Shaked Y; Smith V; Neufeld G
Carcinogenesis; 2013 Oct; 34(10):2370-9. PubMed ID: 23828904
[TBL] [Abstract][Full Text] [Related]
38. Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy.
Gacche RN; Meshram RJ
Biochim Biophys Acta; 2014 Aug; 1846(1):161-79. PubMed ID: 24836679
[TBL] [Abstract][Full Text] [Related]
39. [Vascular perfusion as the origin of neoplasm resistance to radio- and chemotherapy].
Martinive P; Coucke PA
Rev Med Liege; 2010 Mar; 65(3):133-9. PubMed ID: 20411817
[TBL] [Abstract][Full Text] [Related]
40. Molecular and cellular regulators of cancer angiogenesis.
Goh PP; Sze DM; Roufogalis BD
Curr Cancer Drug Targets; 2007 Dec; 7(8):743-58. PubMed ID: 18220534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
